Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental Hydrolyzed infant formula · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Hydrolyzed infant formula | EXPERIMENTAL | Hydrolyzed infant formula to be fed ad libitum |
| Name | Type | Description |
|---|---|---|
| Experimental Hydrolyzed infant formula | OTHER | Experimental hydrolyzed infant formula to be fed ad libitum |
Inclusion Criteria: * Infant is 0 to 180 days of age * Infant with persistent feeding intolerance symptoms; has had at least 1 formula switch OR infant is experiencing/being managed with an extensively hydrolyzed formula for suspected food protein intolerance or allergy or other condition where an ...
Experimental Hydrolyzed infant formula is an investigational product being studied for use in infants with gastrointestinal intolerance. It is a hydrolyzed formula designed for infant nutrition, and it is currently in Phase 3 clinical development by Abbott Laboratories.
Abbott Laboratories (NYSE: ABT) is developing Experimental Hydrolyzed infant formula. The product is an investigational hydrolyzed infant formula intended for infants with gastrointestinal intolerance, and it is currently in Phase 3 clinical development.
Experimental Hydrolyzed infant formula is in Phase 3 clinical development. It is an investigational product, not yet approved, and has completed one Phase 3 trial. The study was a single-arm, uncontrolled trial conducted in the United States.
Experimental Hydrolyzed infant formula has one completed Phase 3 trial, NCT01573871, titled 'Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula.' The study enrolled 25 infants with gastrointestinal intolerance in the United States and was uncontrolled.
Experimental Hydrolyzed infant formula is not FDA approved. It is an investigational product currently in Phase 3 clinical development. One Phase 3 trial has been completed, but the product remains under investigation and has not received regulatory approval.